Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $16.88

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $16.88.

Several equities research analysts have recently weighed in on FOLD shares. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Monday, January 13th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. StockNews.com upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This trade represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in FOLD. OLD Second National Bank of Aurora acquired a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $26,000. Hazlett Burt & Watson Inc. boosted its position in Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 1,569 shares in the last quarter. Blue Trust Inc. grew its holdings in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI purchased a new position in shares of Amicus Therapeutics in the third quarter valued at $32,000. Finally, Covestor Ltd raised its stake in shares of Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 2,312 shares during the last quarter.

Amicus Therapeutics Stock Up 1.3 %

Amicus Therapeutics stock opened at $9.77 on Friday. The company has a market capitalization of $2.92 billion, a P/E ratio of -28.74, a PEG ratio of 1.69 and a beta of 0.61. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.03. The stock has a 50-day simple moving average of $9.60 and a 200-day simple moving average of $10.43.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.